center for ips cell research and application

Honing The (Cancer) Killer Instinct Of iNKT Cells

Reprogramming invariant natural killer T cells in the lab increases their potency and helps them seek out and kill cancer cells.

CiRA & Takeda Announce Joint iPS Cell Research

Takeda, Japan's largest pharmaceutical company, will provide US$166 million of funding for iPS research over the next ten years.

Human iPSC Used To Treat Kidney Injury In Mice

A public-private partnership between CiRA and Astellas has yielded the finding that iPSC could be used to treat acute kidney injury.

CiRA & Takeda Undertake US$267 Million iPS Collaboration

The ten-year research collaboration to be hosted at Takeda's Shonan Research Center will focus on developing clinical applications for iPS cells.